- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00644605
A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension
A Multinational, Multi-centre, Randomised, Double-blind, Double-dummy, Placebo-controlled Study to Assess the Efficacy and Safety of 20, 40, and 80mg TID Sildenafil in the Treatment of Pulmonary Arterial Hypertension in Subjects Aged 18 Years and Over
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Anticipé)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
-
Cape Town, Afrique du Sud, 7700
- Pfizer Investigational Site
-
Johannesburg, Afrique du Sud, 2193
- Pfizer Investigational Site
-
Parow, Afrique du Sud
- Pfizer Investigational Site
-
-
-
-
-
Berlin, Allemagne, 13353
- Pfizer Investigational Site
-
Giessen, Allemagne, 35385
- Pfizer Investigational Site
-
Giessen, Allemagne, 35392
- Pfizer Investigational Site
-
Hannover, Allemagne, 30625
- Pfizer Investigational Site
-
Leipzig, Allemagne, 04103
- Pfizer Investigational Site
-
-
-
-
New South Wales
-
Darlinghurst, New South Wales, Australie, 2010
- Pfizer Investigational Site
-
-
Victoria
-
Melbourne, Victoria, Australie, 3004
- Pfizer Investigational Site
-
-
-
-
-
Bruxelles, Belgique, 1070
- Pfizer Investigational Site
-
Leuven, Belgique, 3000
- Pfizer Investigational Site
-
-
-
-
SP
-
Sao Paulo, SP, Brésil, 05403-900
- Pfizer Investigational Site
-
-
-
-
-
Suwon, Corée, République de, 442-721
- Pfizer Investigational Site
-
-
-
-
-
Kobenhavn, Danemark, 2100
- Pfizer Investigational Site
-
-
-
-
-
Barcelona, Espagne, 08035
- Pfizer Investigational Site
-
Barcelona, Espagne, 08036
- Pfizer Investigational Site
-
Madrid, Espagne, 28041
- Pfizer Investigational Site
-
-
-
-
-
Clamart, France, 92141
- Pfizer Investigational Site
-
-
-
-
-
Shatin N T, Hong Kong
- Pfizer Investigational Site
-
-
-
-
Pest
-
Budapest, Pest, Hongrie, 1529
- Pfizer Investigational Site
-
-
Zala
-
Zalaegerszeg, Zala, Hongrie, 8900
- Pfizer Investigational Site
-
-
-
-
-
Petach Tikva, Israël, 49100
- Pfizer Investigational Site
-
Tel Hashomer, Israël, 52621
- Pfizer Investigational Site
-
-
-
-
-
Bologna, Italie, 40138
- Pfizer Investigational Site
-
Pisa, Italie, 56124
- Pfizer Investigational Site
-
Pisa, Italie, 56126
- Pfizer Investigational Site
-
-
-
-
-
Kuala Lumpur, Malaisie, 59100
- Pfizer Investigational Site
-
-
-
-
-
Tlalpan, Mexique
- Pfizer Investigational Site
-
-
-
-
-
Oslo, Norvège, NO-0027
- Pfizer Investigational Site
-
-
-
-
-
Amsterdam, Pays-Bas, 1081 HV
- Pfizer Investigational Site
-
-
-
-
-
Katowice, Pologne, 40-057
- Pfizer Investigational Site
-
Warszawa, Pologne, 01-138
- Pfizer Investigational Site
-
Warszawa, Pologne, 03-709
- Pfizer Investigational Site
-
Zabrze, Pologne, 41-800
- Pfizer Investigational Site
-
-
-
-
-
Glasgow, Royaume-Uni, G11 6NT
- Pfizer Investigational Site
-
HIGH Heaton, Newcastle-upon-tyne, Royaume-Uni, NE7 7DW
- Pfizer Investigational Site
-
-
Cambridgeshire
-
Papworth Everard, Cambridgeshire, Royaume-Uni, CB3 8RE
- Pfizer Investigational Site
-
-
South Yorkshire
-
Sheffield, South Yorkshire, Royaume-Uni, S10 2JF
- Pfizer Investigational Site
-
-
-
-
-
Singapore, Singapour, 168752
- Pfizer Investigational Site
-
-
-
-
-
Goteborg, Suède, 413 45
- Pfizer Investigational Site
-
Molndal, Suède, 431 80
- Pfizer Investigational Site
-
-
-
-
-
Prague 4, Tchéquie, 140 00
- Pfizer Investigational Site
-
Prague 4, Tchéquie, 140 21
- Pfizer Investigational Site
-
-
-
-
Alabama
-
Birmingham, Alabama, États-Unis, 35233
- Pfizer Investigational Site
-
Birmingham, Alabama, États-Unis, 35294
- Pfizer Investigational Site
-
Birmingham, Alabama, États-Unis, 35294-0006
- Pfizer Investigational Site
-
-
California
-
La Jolla, California, États-Unis, 92037
- Pfizer Investigational Site
-
La Jolla, California, États-Unis, 92093
- Pfizer Investigational Site
-
Los Angeles, California, États-Unis, 90095
- Pfizer Investigational Site
-
Los Angeles, California, États-Unis, 90033
- Pfizer Investigational Site
-
Los Angeles, California, États-Unis, 90024
- Pfizer Investigational Site
-
San Diego, California, États-Unis, 92037
- Pfizer Investigational Site
-
Torrance, California, États-Unis, 90502
- Pfizer Investigational Site
-
Torrance, California, États-Unis, 90509
- Pfizer Investigational Site
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80010
- Pfizer Investigational Site
-
Denver, Colorado, États-Unis, 80262
- Pfizer Investigational Site
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60612
- Pfizer Investigational Site
-
-
Louisiana
-
Shreveport, Louisiana, États-Unis, 71103
- Pfizer Investigational Site
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21205
- Pfizer Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02111
- Pfizer Investigational Site
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48109
- Pfizer Investigational Site
-
-
Minnesota
-
Rochester, Minnesota, États-Unis, 55905
- Pfizer Investigational Site
-
-
New York
-
New York, New York, États-Unis, 10032
- Pfizer Investigational Site
-
-
North Carolina
-
Durham, North Carolina, États-Unis, 27710
- Pfizer Investigational Site
-
-
Tennessee
-
Nashville, Tennessee, États-Unis, 37232
- Pfizer Investigational Site
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- Pfizer Investigational Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, États-Unis, 53215
- Pfizer Investigational Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
Included patients had primary pulmonary arterial hypertension, pulmonary hypertension secondary to connective tissue disease, or pulmonary hypertension with surgical repair at least 5 years previously; a mean pulmonary artery pressure greater than or equal to 25 mmHg and a pulmonary artery wedge pressure of less than or equal to 15 mmHg at rest, via right heart catheterisation within 21 days prior to randomisation; and a baseline 6-Minute Walk test distance of 100 m to 450 m.
Exclusion Criteria:
Subjects with congenital heart disease, pulmonary hypertension due to thromboembolism, HIV, chronic obstructive airway disease, congestive heart failure or schistosomiasis; subjects with significant (ie > 2+) valvular disease other than tricuspid regurgitation or pulmonary regurgitation; and acutely decompensated heart failure within the previous 30 days; subjects with pulmonary hypertension secondary to any other etiology other than those specified in the inclusion criteria.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Comparateur actif: Bras 2
|
sildenafil 40 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
sildenafil 80 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks; initially, patients received 40mg TID for one week and were then up-titrated to 80mg TID
sildenafil 20 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
|
Comparateur actif: Bras 1
|
sildenafil 40 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
sildenafil 80 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks; initially, patients received 40mg TID for one week and were then up-titrated to 80mg TID
sildenafil 20 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
|
Comparateur placebo: Bras 4
|
placebo by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
|
Comparateur actif: Bras 3
|
sildenafil 40 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
sildenafil 80 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks; initially, patients received 40mg TID for one week and were then up-titrated to 80mg TID
sildenafil 20 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Change from baseline in exercise capacity, as measured by distance walked in six minutes (6-Minute Walk test).
Délai: Week 12
|
Week 12
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Change from baseline in mean pulmonary arterial pressure
Délai: Week 12
|
Week 12
|
Time from randomisation to the first occurrence of clinical worsening (death or lung transplantation or hospitalisation due to pulmonary hypertension or initiation of prostacyclin therapy or initiation of bosentan therapy)
Délai: Week 0 to 12
|
Week 0 to 12
|
Change from baseline in the BORG dyspnoea score
Délai: Week 12
|
Week 12
|
Change from baseline in pulmonary hypertension criteria for functional capacity and therapeutic class
Délai: Week 12
|
Week 12
|
Change from baseline in the 8 dimensions of SF-36 (Physical functioning, Role functioning, Bodily pain, General health, Vitality, Social functioning, Mental health and Reported health transition)
Délai: Week 4 and Week 12
|
Week 4 and Week 12
|
Change from baseline at Weeks 4 and 12 in the 5 dimensions of ED5Q (Mobility, Self care, Usual Activities, Pain/Discomfort and Anxiety/Depression)
Délai: Week 4 and Week 12
|
Week 4 and Week 12
|
Patient overall preference assessment
Délai: Week 12
|
Week 12
|
Change in Chronic Use of Background Therapy for Pulmonary Arterial Hypertension
Délai: throughout the study
|
throughout the study
|
Change from baseline in hemodynamic parameters
Délai: Week 12
|
Week 12
|
Collaborateurs et enquêteurs
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies cardiovasculaires
- Maladies vasculaires
- Maladies des voies respiratoires
- Maladies pulmonaires
- Hypertension
- Hypertension artérielle pulmonaire
- Hypertension pulmonaire
- Mécanismes moléculaires de l'action pharmacologique
- Agents vasodilatateurs
- Agents urologiques
- Inhibiteurs d'enzymes
- Inhibiteurs de la phosphodiestérase
- Inhibiteurs de la phosphodiestérase 5
- Citrate de sildénafil
Autres numéros d'identification d'étude
- A1481140
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Hypertension pulmonaire
-
National Taiwan University Hospital Hsin-Chu BranchRecrutementHypertension Essentielle | Hypertension, masquéTaïwan
-
University of Alabama at BirminghamTroy UniversityComplétéHypertension | Hypertension, résistante à la thérapie conventionnelle | Hypertension non contrôlée | Hypertension, blouse blancheÉtats-Unis
-
Amsterdam UMC, location VUmcZonMw: The Netherlands Organisation for Health Research and DevelopmentInconnue
-
Vanderbilt University Medical CenterJohns Hopkins UniversityComplétéHypertension artérielle pulmonaire | Hypertension artérielle pulmonaire idiopathique | Hypertension artérielle pulmonaire associée | Hypertension artérielle pulmonaire héréditaireÉtats-Unis
-
Centre Chirurgical Marie LannelongueInconnueHypertension pulmonaire thromboembolique chronique et hypertension artérielle pulmonaireFrance
-
Assistance Publique - Hôpitaux de ParisActif, ne recrute pasHypertension portale non cirrhotique intrahépatiqueFrance
-
University of Kansas Medical CenterRecrutementHypertension artérielle pulmonaire | Hypertension pulmonaire | Hypertension pulmonaire thromboembolique chronique | Hypertension pulmonaire due à une cardiopathie gauche | Hypertension pulmonaire, primaire, 4 | Hypertension pulmonaire, primaire, 2 | Hypertension pulmonaire, primaire, 3 | Hypertension... et d'autres conditionsÉtats-Unis
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldComplétéHypertension artérielle pulmonaire idiopathique | Hypertension pulmonaire thromboembolique chroniqueRoyaume-Uni
-
BayerComplété
-
AstraZenecaComplétéHypertension artérielle (hypertension).
Essais cliniques sur sildenafil
-
Pfizer's Upjohn has merged with Mylan to form Viatris...Complété
-
Virginia Commonwealth UniversityBayerComplété
-
Neutec Ar-Ge San ve Tic A.ŞComplétéDysérection | Éjaculation précoceTurquie
-
Johns Hopkins UniversityNational Heart, Lung, and Blood Institute (NHLBI); National Center for Advancing...RecrutementHypertension pulmonaire pédiatriqueÉtats-Unis, Canada
-
Amsterdam UMC, location VUmcInconnueHypertension artérielle pulmonairePays-Bas